Get the Stockscreener App
53.93
2.31%
+1.22
After Hours:
54.20
0.27
+0.50%
Cytokinetics Inc stock is currently priced at $53.93, with a 24-hour trading volume of 1.16M.
It has seen a +2.31% increased in the last 24 hours and a -9.15% declined in the past month.
The chart indicates a potential bullish trend, as the stock is above the $53.26 pivot point. If it approaches the $55.00 resistance level, significant changes may occur.
Previous Close:
$52.71
Open:
$52.23
24h Volume:
1.16M
Market Cap:
$5.53B
Revenue:
$3.75M
Net Income/Loss:
$-530.60M
P/E Ratio:
-9.7699
EPS:
-5.52
Net Cash Flow:
$-421.55M
1W Performance:
+2.16%
1M Performance:
-9.15%
6M Performance:
+47.31%
1Y Performance:
+54.04%
1D Range:
$51.87
$54.35
52W Range:
$25.98
$110.25
Cytokinetics Inc Stock (CYTK) Company Profile
Name
Cytokinetics Inc
Sector
Industry
Phone
650-624-3000
Address
280 East Grand Avenue, South San Francisco, CA
Cytokinetics Inc Stock (CYTK) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-24-24 | Downgrade | UBS | Buy → Neutral |
| Jan-05-24 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Nov-09-23 | Initiated | Goldman | Buy |
| Nov-07-23 | Initiated | B. Riley Securities | Buy |
| Aug-15-23 | Initiated | SVB Securities | Outperform |
| Feb-17-23 | Initiated | BofA Securities | Neutral |
| Dec-23-22 | Reiterated | Needham | Buy |
| Dec-20-22 | Initiated | Truist | Buy |
| Oct-11-22 | Initiated | UBS | Buy |
| Jan-28-22 | Initiated | Goldman | Buy |
| Dec-22-21 | Initiated | Oppenheimer | Outperform |
| Dec-10-21 | Initiated | JP Morgan | Overweight |
| Oct-07-21 | Initiated | Jefferies | Buy |
| Mar-12-21 | Initiated | Wolfe Research | Outperform |
| Feb-18-21 | Initiated | Barclays | Overweight |
| Jan-20-21 | Reiterated | H.C. Wainwright | Buy |
| Oct-29-20 | Initiated | Goldman | Neutral |
| Jul-10-20 | Initiated | Raymond James | Strong Buy |
| May-05-20 | Initiated | Mizuho | Buy |
| Apr-09-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Sep-21-18 | Initiated | Cantor Fitzgerald | Overweight |
| Sep-10-18 | Resumed | Morgan Stanley | Equal-Weight |
| Nov-22-17 | Reiterated | Morgan Stanley | Overweight |
| Nov-22-17 | Downgrade | Needham | Strong Buy → Buy |
| Nov-21-17 | Reiterated | H.C. Wainwright | Buy |
| Jul-31-17 | Initiated | Morgan Stanley | Overweight |
| Mar-08-17 | Initiated | Rodman & Renshaw | Buy |
| Feb-06-17 | Upgrade | Needham | Buy → Strong Buy |
| Dec-16-16 | Initiated | Cantor Fitzgerald | Overweight |
| Jul-28-16 | Reiterated | Needham | Buy |
| Nov-10-15 | Reiterated | FBR Capital | Outperform |
| Nov-09-15 | Reiterated | ROTH Capital | Buy |
| Jul-24-15 | Reiterated | MLV & Co | Buy |
| Dec-31-14 | Reiterated | ROTH Capital | Buy |
| Nov-04-14 | Upgrade | MLV & Co | Hold → Buy |
| Apr-28-14 | Reiterated | Needham | Buy |
View All
Cytokinetics Inc Stock (CYTK) Latest News
Cytokinetics Inc (CYTK) can make a big difference with a little luck – Sete News - SETE News
SETE News
Cytokinetics Inc (CYTK) presents a great opportunity, but the stock is slightly overvalued – US Post News - US Post News
US Post News
Selling Buzz: Cytokinetics Inc [CYTK] EVP Research & Development Malik Fady Ibraham sells 7788 shares of the ... - Knox Daily
Knox Daily
Bayesian Capital Management LP Acquires Shares of 38674 Cytokinetics, Incorporated (NASDAQ:CYTK) - Defense World
Defense World
Financial Metrics Unveiled: Cytokinetics Inc (CYTK)'s Key Ratios in the Spotlight – DWinneX - The Dwinnex
The Dwinnex
Cytokinetics, Incorporated (NASDAQ:CYTK) EVP Fady Ibraham Malik Sells 7788 Shares - Defense World
Defense World
Cytokinetics Inc Stock (CYTK) Financials Data
Cytokinetics Inc (CYTK) Revenue 2024
CYTK reported a revenue (TTM) of $3.75 million for the quarter ending March 31, 2024, a -96.17% decline year-over-year.
Cytokinetics Inc (CYTK) Net Income 2024
CYTK net income (TTM) was -$530.60 million for the quarter ending March 31, 2024, a -23.17% decrease year-over-year.
Cytokinetics Inc (CYTK) Cash Flow 2024
CYTK recorded a free cash flow (TTM) of -$421.55 million for the quarter ending March 31, 2024, a -3.89% decrease year-over-year.
Cytokinetics Inc (CYTK) Earnings per Share 2024
CYTK earnings per share (TTM) was -$5.40 for the quarter ending March 31, 2024, a -17.90% decline year-over-year.
Cytokinetics Inc Stock (CYTK) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Malik Fady Ibraham | EVP Research & Development |
Jun 11 '24 |
Sale |
53.04 |
7,788 |
413,106 |
135,004 |
| Bhanji Muna | Director |
Jun 10 '24 |
Sale |
52.07 |
2,000 |
104,140 |
17,631 |
| Blum Robert I | President & CEO |
Jun 04 '24 |
Sale |
48.85 |
22,500 |
1,099,125 |
439,145 |
| PARSHALL B LYNNE | Director |
Jun 03 '24 |
Option Exercise |
10.68 |
5,000 |
53,400 |
20,600 |
| Wong Robert | VP, Chief Accounting Officer |
Jun 03 '24 |
Sale |
48.88 |
13,011 |
635,978 |
16,653 |
| PARSHALL B LYNNE | Director |
Jun 03 '24 |
Sale |
48.64 |
5,000 |
243,200 |
15,600 |
| Harrington Robert Arthur | Director |
Jun 03 '24 |
Sale |
48.64 |
1,580 |
76,851 |
15,541 |
| Malik Fady Ibraham | EVP Research & Development |
May 07 '24 |
Option Exercise |
6.67 |
14,186 |
94,621 |
152,603 |
| Malik Fady Ibraham | EVP Research & Development |
May 07 '24 |
Sale |
65.11 |
15,547 |
1,012,265 |
137,056 |
| HENDERSON JOHN T | Director |
Apr 25 '24 |
Sale |
64.54 |
10,562 |
681,671 |
32,070 |
About Cytokinetics Inc
Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. It is developing small molecule drug candidates primarily engineered to increase muscle function and contractility. The company's drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in phase III clinical trials in patients with heart failure; and reldesemtiv, a fast skeletal muscle activator, which is in two phase II clinical trials in patients with spinal muscular atrophy and amyotrophic lateral sclerosis. It also develops reldesemtiv that is in phase II clinical trials in patients with chronic obstructive pulmonary disease, as well as in phase Ib clinical trials in elderly subjects with limited mobility. The company has strategic alliances with Astellas Pharma Inc. and Amgen Inc. The company was founded in 1997 and is headquartered in South San Francisco, California.
0.87%
0.21%
Cap:
|
Volume (24h):